The peptide Tat-NR2B9c (also termed NA-1) is developed from the discovery that postsynaptic density protein-95, the NMDA receptor-interacting protein, is a hub for excitotoxic signaling and a stroke therapeutic target (Aarts et al., 2002; Cui et al., 2007). The gene discussed is DLG4; the disease is stroke disorder.